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Recently, there have been several major technical advances in the sonographic diagnosis of ovarian cancer in its early stages. These
include improved assessment of tumor morphology with transvaginal sonography (TVS), and detection and characterization of
tumor neovascularity with transvaginal color Doppler sonography (TV-CDS) and contrast-enhanced transvaginal sonography
(CE-TVS). This paper will discuss and illustrate these improvements and describe how they enhance detection of early-stage
ovarian cancer. Our initial experience with parametric mapping of CE-TVS will also be mentioned.
1.Introduction
This year in the United States approximately 24,000 women
will be diagnosed with ovarian cancer, and there will be
approximately14,000associateddeaths,predominantlyfrom
epithelial ovarian cancer (EOC). Worldwide, it is estimated
that 204,449 patients with ovarian cancer will be diagnosed
this year with an estimated 124,860 disease-related deaths.
The incidence of ovarian cancer has been steadily increasing
over the past 10 years, with an overall lifetime risk of 1.8%
[3]. Despite improvements in surgical techniques and new
chemotherapeutic regimens, the overall survival for women
with stage III/IV EOC has remained relatively unchanged
(15%) over the past 40 years [3]. In contrast, women
diagnosedwithdiseaseconﬁnedtotheovary(stageI)require
less morbid surgical intervention, may not require adjuvant
chemotherapy, have a signiﬁcantly improved quality of
life, and most importantly have an overall 5-year survival
approximating 90% [3]. Unfortunately, 75% of women
continue to be diagnosed with advanced-stage disease. It is
thought that accurate diagnosis of EOC at an earlier stage
may decrease overall disease-related mortality.
Evaluation of adnexal masses can be performed with sev-
eral imaging methods, including TVS, computed tomogra-
phy (CT), magnetic resonance imaging (MRI), and positron
emission tomography (PET). CT can detect large adnexal
masses but has lower sensitivity for small adnexal masses,
especially in thin patients in whom adnexal lesions can be
misinterpreted as other pelvic structures or loops of pelvic
small bowel. Furthermore, the ability of CT to characterize
adnexal lesions as benign or malignant is limited by low
inherent tissue contrast, with the notable exception of
ovarian dermoids that can be characterized based on the
presence of macroscopic fat and/or calciﬁcation. MRI oﬀers
higher spatial and contrast resolution than CT and can
characterize a wider spectrum of adnexal lesions based on
magnetic signal properties or enhancement behavior, but
accuracyofMRImaydiminishforborderlineovariantumors
and small ovarian masses. Compared to TVS, MRI is costly
and has limited availability [4]. PET can identify aggressive2 Journal of Oncology
adnexal lesions on the basis of increased ﬂuorodeoxyglucose
(FDG) uptake, but it suﬀers from low speciﬁcity for small
lesions, noting that normal premenopausal ovaries will
demonstrate increased metabolic activity at mid cycle, and
a physiological corpus luteum can therefore mimic an
aggressive malignancy. The accuracy of PET is also limited
secondary to false negatives in borderline ovarian neoplasms
[5].
TVS is widely available and oﬀers high-resolution imag-
ing without the use of ionizing radiation. For these reasons,
TVS is the initial diagnostic modality of choice for the
evaluation of most patients with a pelvic mass. As previously
mentioned, TVS has limited sensitivity and speciﬁcity for the
deﬁnitive diagnosis of ovarian cancer because of overlapping
morphologic features seen in benign and malignant lesions.
Recently, however, signiﬁcant technologic advances have
yielded vast improvements in the sonographic depiction
of early-stage ovarian cancer, and these improvements
have translated into improved sonographic discrimination
of benign from malignant disease in preliminary studies.
Combined evaluation of sonographic morphology and CDS
forms a set of basic “simple rules” for sonographic distinc-
tion of benign from malignant ovarian masses based on
the data derived from a European multicenter study which
included 1,223 adnexal tumors (sensitivity 93%; speciﬁcity
90%) [6]( Table 1).
Three-dimensional transvaginal sonography (3D TVS)
has improved the morphologic depiction of ovarian cancers
beyond the capabilities of traditional TVS. Improvements
in transvaginal color Doppler sonography (TV-CDS) have
enhanced sonographic assessment of large tumor vascular
networks, and contrast-enhanced transvaginal sonography
(CE-TVS) now allows for interrogation of tumor microvas-
cularity [7–9]. This paper discusses these newer techniques,
speciﬁcally CE-TVS, with emphasis on their advantages and
areas for potential improvement.
1.1. 2D and 3D TVS. Conventional sonographic criteria
for ovarian cancer diagnosis are based on morphological
classiﬁcation of ovarian masses. Ovarian malignancy is
unlikely in simple cysts with smooth walls, but presence of
a solid mass or solid projections (papillary excrescences) into
the cyst cavity signiﬁcantly increases the risk of malignancy.
Hirai has described the morphologic features on TVS
associated with stage I ovarian cancer in a lay-screening
population in Japan [1] (Figures 1, 2,a n d3). In general, the
stage IA ovarian cancers with normal CA-125 were small and
hadlesssolidcomponentsthanstageIAcancerswithelevated
CA-125. Papillary excrescences typically occur in areas of
epithelial neoplasia and can be seen borderline rather than
frankly malignant lesions.
Over the last 10 years, the diagnostic accuracy for
conventional 2D TVS has been improving [10]. A 1997 study
reported that gray-scale sonography identiﬁed malignant
tumors with a sensitivity of 91% and a speciﬁcity of 84%
[11], while a 2008 study found a sensitivity of 93% and
speciﬁcity of 90% [12]. As the result of these studies,
several morphological scoring systems have been developed
Table 1: “Simple rules” for sonographic diagnosis of ovarian
cancer∗.
Benign Malignant
(1) Unilocular cyst (1) Irregular solid tumor
(2) Solid components <7mm (2)Ascites
(3) Acoustic shadows (3) Papillary excrescences
(4) Smooth multilocular (4) Irregular multiloculated/solid
tumor
<10cm >10cm
(5) No color Doppler ﬂow (5) Very high color content
∗Timmerman, D, US O/G 31:681, 2008.
for sonography, including features such as the presence
of papillary projections or irregular and/or thick septae.
Results of a meta-analysis provide evidence that sonographic
techniques that combine gray-scale morphologic assessment
with tumor vascularity mapping are signiﬁcantly better
in ovarian lesion characterization than Doppler arterial
resistance measurements, color Doppler ﬂow imaging, or
gray-scale morphologic information alone [13].
The recent development of 3D-TVS improves the detec-
tion of morphologic abnormalities indicative of neoplastic
ovarian masses. In particular, small papillary excrescences
or focal wall (mural) irregularities can be detected which
are associated with epithelial malignant growth in ovarian
masses [8]. The recent advent of matrix array transduc-
ers/probes may improve visualization of both internal and
external wall (capsular) abnormalities, increase comfort for
the patient, and increase reproducibility.
1.2. Transvaginal Color Doppler Sonography (TV-CDS). TV-
CDS provides depiction of the macrovascularity (over 200µ)
of tumors but does not delineate microscopic (capillary)
tumor neovascularity. The vascular network in tumors can
be further interrogated using Doppler techniques to indicate
the impedance within vessels [7, 8]. This in turn roughly
reﬂects pressure gradients.
Combining morphologic assessment with TVS with
color Doppler features has allowed accurate assessments of
whether a mass is benign or malignant by following “simple
rules” [6]. Using color Doppler techniques, the overall
vascularity was classiﬁed as high, low, or intermediate, rather
than determining vascular indices such as resistance or
pulsatility. In a European multicentered study, it was shown
that this paradigm resulted in 90% sensitivity and 92%
sensitivity [6].
1.3. Contrast-Enhanced Transvaginal Sonography (CE-TVS).
Both micro- and macroscopically, tumor neovascularity is
characterized as vessels that demonstrate irregular caliber
and branching. TV-CDS can only detect ﬂow in rela-
tively large vessels. Microvascular (i.e., capillary) tumor
neovascularity can be depicted using microbubble contrast
(Figures 4, 5,a n d6). On dynamic CE-TVS malignant
tumor neovascularity usually demonstrates a higher peakJournal of Oncology 3
(a) Irregular solid area in a mucinous cystadenocarcinoma
(b) Papillary excrescences in a clear cell carcinoma
(c) Mural nodules in an endometrioid cancer
(d) Irregular septa and echogenic solid foci within immature teratoma
Figure 1: Morphologic signs of malignancy with histopathologic correlation on TVS in various histologic types of stage 1A ovarian cancer.4 Journal of Oncology
(a) (L) TVS of bilobed cystic ovarian mass containing a papillary excrescence in one locule. (R) CDS showing ﬂow
within papillary excrescence
(b) Photomicrographs of histology showing vessels in (L) low power, (R) high power
Figure 2: 2D CDS of showing ﬂow within papillary excrescence within a papillary cystadenoﬁbroma.
(a) 2D TV-CDS of papillary cystadenoma showing
low-impedance ﬂow within a papillary excrescence
(b) 3D TVS (surface rendition) showing papillary
excrescences
Figure 3: 3D TV-CDS of papillary excrescences within a papillary serous cystadenoma.
of contrast enhancement and prolonged contrast washout
when compared to benign tumors [1, 9, 14, 15]( Figure 9).
In our previous study, all malignant tumors and 50%
of benign tumors showed detectable contrast enhancement
(image intensity > 10% above the baseline) after microbub-
ble injection [9]. When contrast enhancement dynamics
were assessed, we found that malignant lesions had a similar
timetopeak(Tp;26.2 ± 5.9v ersus29.8 ± 13.4seconds;P =
.4), greater peak enhancement (PE; 21.3 ± 4.7v e r s u s8 .3 ±
5.7dB;P< . 001), a longer half wash-out time ((1/2)Two;
104.2 ± 48.1v e r s u s3 2 .2 ± 18.9 seconds; P< . 001), and
a greater area under the curve (AUC; 1807.2 ± 588.3v e r s u s
413.8 ± 294.8 seconds−1; P< . 001) when compared with
enhancing benign lesions (Figure 9).
AUC greater than 787 seconds−1 was the most accu-
rate diagnostic criterion for ovarian cancer, with 100.0%
sensitivity and 96.2% speciﬁcity. Additionally, PE greater
than 17.2dB (90.0% sensitivity and 98.3% speciﬁcity) andJournal of Oncology 5
(a) Top: long axis showing central ﬂow with an
irregularly shaped solid adnexal mass. Bottom: same
as top in short axis
(b) Top: 3D TV-CDS showing (combined volume
redition) cluster of vessels within morphologically
abnormal area. Bottom: coronal
Figure 4: 3D TV-CDS of papillary cystadenocarcinoma showing multiplanar reconstruction (MPR) images.
(a) Solid mass with no internal ﬂow with fundamental (top right of
image) and harmonic (top left) images. Time intensity curve shows
relatively high peak enhancement and short wash-out time
(b) Parametric images showing little internal ﬂow
Figure 5: CE-TVS of a benign ﬁbroma.
a( 1 /2)Two of greater than 41.0 seconds (100.0% sensi-
tivity and 92.3% speciﬁcity) proved to be useful. Initial
analysis of contrast-enhanced kinetic was done using time
intensity curves for mean, standard deviation, and P value
(Figures 9 and 11) and subsequently by receive operator
characteristic curves for vascular index (VI); ﬂow index (FI);
vascular ﬂow index (VFI) (Figure 12). The receiver operator
characteristics of each parameter is shown in Figure 13
with predetermined cutoﬀ values as established with receive
operation curves and compared to VI, FI, and VFI values.
These results show that contrast-enhanced nonlinear pulse
inversion sonography is a more appropriate method for
characterizing blood ﬂow dynamics in ovarian tumors than
by TV-CDS and can provide an important tool to aid
diﬀerentialdiagnosesbetweenbenignandmalignantovarian
tumors.6 Journal of Oncology
(a) (R) Fundamental and (L) harmonic image showing mural nodule.
Thereisquickwash-inandwash-outwithinthemuralnoduleindicating
benignancy
(b) Parametric image showing diﬀerent time of arrivals within mural
nodule, wall, and septum
Figure 6: CE-TVS of serous cystadenoma with mural nodules.
(a) (R) Fundamental image showing mural nodule and mobile
echogenic material (L), same using harmonic imaging. There is quick
wash-in and long washout within the mural nodule
(b) Parametric image diﬀerent time of arrival for mural module versus
wall
Figure 7: CE-TVS of borderline mucinous (intestinal) cystadenocarcinoma.
(a) (R) TVS shows normal sized ovary with small cystic area. (L) CDS
shows marked vascularity within ovary. Time-intensity curve shows
high peak intensity and long washout
(b) Parametric image showing diﬀuse vascularity
Figure 8: CE-TVS of stage I papillary serous cystadenocarcinoma.Journal of Oncology 7
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Figure 9: Box graph of contrast-enhanced parameters. While there is no diﬀerence in time of peak (T wash-in), there are signiﬁcant
diﬀerences in peak enhancement, wash-out time and vascularity ((b), (c); (d)) from [1].
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Figure 10: Sensitivities and speciﬁcities of maximum enhance-
ment, wash-in, wash-out and area under curve (AUC). Maximum
enhancement, wash-out and AUC had greatest accuracy.
1.4. Parametric Mapping of CE-TVS. While the time-
intensity curve has traditionally been calculated from mean
signal intensities over a region of interest, parametric
mapping of time-intensity curve variables on a pixel-by-
pixel basis allows for more global visualization of tumor
hemodynamics. The use of this technique in ovarian cancer
has been limited to selecting the pixel with greatest peak
enhancement(PE)andusingthatpixel’stime-intensitycurve
for further analysis [15]. However, parametric maps of
CE-TVS have recently been used with limited success for
diﬀerentiation of benign and malignant focal liver lesions
[16] and breast lesions [17, 18]. Preliminary results for using
parametric mapping of ovarian tumors seem to indicate
signiﬁcant potential for improving diagnostic accuracy.
Our preliminary results from a subset of 29 out of
the 57 subjects analyzed in our previous region of interest
(ROI) study show potential for this technique to diﬀerentiate
benign and malignant ovarian masses [19]. The methods
of data acquisition are outlined in the previously described
study [9]. Analysis with a quantiﬁcation software prototype
(Bracco Suisse SA, Geneva, Switzerland) utilized parametric
maps of Tp (sec), PE (dB), and wash-in AUC (wiAUC;
arbitraryunits,a.u.).Theregionofinterestwaskeptconstant
in size between subjects and was corrected for motion.
The map color scales were adjusted such that abnormal
hemodynamics were represented by red for PE > 24a.u,
Tp < 11s,a n dw i A U C > 35a.u. (cutoﬀs chosen at optimum
points on receiver operator characteristics curve), and the
presenceofanyredcolorwasusedtodiﬀerentiatebenignand
malignant tumors.8 Journal of Oncology
0
20
40
60
80
100
0 2 04 06 08 0 1 0 0
100-speciﬁcity
S
e
n
s
i
t
i
v
i
t
y
Time from bolus injection to maximum
(a)
0
20
40
60
80
100
0 2 04 06 08 0 1 0 0
100-speciﬁcity
S
e
n
s
i
t
i
v
i
t
y
Maximum enhancement
(b)
0
20
40
60
80
100
0 2 04 06 08 0 1 0 0
100-speciﬁcity
S
e
n
s
i
t
i
v
i
t
y
Wash-out time
(c)
0
20
40
60
80
100
0 2 04 06 08 0 1 0 0
100-speciﬁcity
S
e
n
s
i
t
i
v
i
t
y
Area under the curve
(d)
Figure 11: Receiver operator characteristerics for (a) wash-in, (b) maximum enhancement, (c) wash-out, and (d) area under curve.
The preliminary results from the subanalysis of 18
benign and 11 histologically proven malignant ovarian
masses showed greatest diagnostic accuracy for maps of PE
(sensitivity 100%, speciﬁcity 67%) and wiAUC (sensitivity
73%, speciﬁcity 94%), while maps of Tp were least accurate
(sensitivity 100%, speciﬁcity 17%). Final analysis of all 57
subjects is needed to determine the ultimate utility of these
methods, but preliminary results are promising.
2. Discussion
CE-TVS can signiﬁcantly improve the diagnostic ability of
transvaginal sonography alone to identify early microvascu-
lar changes that are known to be associated with early-stage
ovarian cancer [1, 9, 14, 15, 20]. Currently, contrast agents
play a pivotal role in the imaging modalities of CT and MRI
by increasing lesion conspicuity, accentuating morphologicJournal of Oncology 9
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Figure 12: Receiver operator characteristic of various parameters
showing cutoﬀ points for vascular index (VI), ﬂow index (FI), and
vascular ﬂow index (VFI) (from [2]).
features within a lesion, and deﬁning time-resolved lesion
enhancement patterns that serve as additional imaging
parameters by which a lesion may be characterized. Indeed,
contrast agents have received such widespread acceptance
that a CT exam performed without intravenous contrast
or an MRI without contrast for many indications is now
considered limited. Preclinical studies demonstrated that
the intravenous contrast agents for sonography hold great
promise in a multitude of potential clinical applications,
especially in identifying aberrant vascular changes associated
with malignancy [19, 21].
Previous studies have addressed the use of CE-TVS for
benign and malignant tumors by showing greater enhance-
ment of malignant tumors on Doppler imaging. According
to the initial work reported by Kupesic and Kurjak, the use of
a contrast agent with 3D power Doppler sonography showed
very high diagnostic eﬃciency (95.6%) that was superior to
thatofnonenhanced3DpowerDopplersonography(86.7%)
[22]. However, simple documentation of tumor enhance-
ment may not be suﬃcient because some benign tumors
show detectable contrast enhancement. This limitation can
be addressed by assessment of the contrast enhancement
kinetics. Only a few studies have been published that used
kinetic parameters of the contrast agent to compare benign
withmalignanttumorsinthepowerDopplermode.Ordenet
al. demonstrated that after microbubble contrast agent injec-
tion,malignantandbenignadnexallesionsbehavediﬀerently
in degree, onset, and duration of Doppler US enhancement.
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Figure 13: Relative accuracy (sensitivity and speciﬁcity of enhance-
ment kinetic parameters) of various techniques using predeter-
mined cutoﬀ points of: 2D VFI (>0.4), 3D VFI (>0.5), CE-TVS
(max >17.2 dB), CE-TVS ((1/2)Two > 41sec), CE-TVS (AUC >
787s−1).
Dopplercontrast-enhancedparametersinthatstudyhad79–
100% sensitivity and 77–92% speciﬁcity [23]. Marret et al.
reported that wash-out times and AUC were signiﬁcantly
greater in ovarian malignancies than in other benign tumors
(P< . 001), leading to sensitivity estimates between 96% and
100% and speciﬁcity estimates between 83 and 98% [14].
They concluded that Doppler contrast-enhanced parameters
had slightly higher sensitivity and slightly lower speciﬁcity
when compared with transvaginal sonographic variables of
the resistive index and serum CA-125 levels [15].
Our preliminary clinical studies explored diﬀerences in
enhancementparametersinbenignversusmalignantovarian
masses using a new method of CE-TVS termed pulse inver-
sion nonlinear imaging [9]. This method produces more
reliable estimates of tumor microvascular perfusion and
provides more consistent results compared to Doppler-based
contrast-enhanced ultrasound. Our data suggest that, except
fortheTp,contrastenhancementparametersaresigniﬁcantly
diﬀerent in benign versus malignant ovarian masses. The Tp
probably reﬂects intrinsic circulation depending on cardiac
contraction, blood pressure, and overall vascular tone. Once
bloodcirculatesthroughthetumor,however,diﬀerencesmay
reﬂecttheuniquebranchingpatternsandvesselmorphologic
characteristics in the microvascularity of the tumors.
As a general statement, contrast enhancement patterns
signiﬁcantly diﬀer between benign and malignant ovarian
masses. The addition of a vascular sonographic contrast
agent allows a more complete delineation of the vascular
anatomy through enhancement of the signal strength from
small vessels (capillaries) and provides an entirely new
opportunity to time the transit of an injected bolus. CE-TVS
has higher sensitivity and speciﬁcity to diﬀerentiate between
benign and malignant lesions than conventional TVS and for
detecting occult stage I disease.10 Journal of Oncology
2.1. Future Improvements in CE-TVS. CE-TVS can detect
tumor neovascularity (Figures 4, 5, 6, 7,a n d8). Tumor
neovascularity is characterized by vessels with abnormal
endothelialstructurethatareirregularincaliberandbranch-
ing patterns. In order to recognize these features, contrast
enhancement kinetics show relatively high vascular volume
(AUC) and PE. These parameters seem to be best depicted
using time-intensity curves. These parameters may also be
shown in a parametric map, which allows for stricter cutoﬀ
criterion than ROI analysis, as peak values are visualized on a
much ﬁner scale than typical ROIs. The traditional approach
of calculating the time-intensity curve over ROIs chosen on
morphology alone allows small areas of neovascularity to
be missed, as they are averaged over larger heterogeneous
areas. The primary utility of parametric mapping of ovarian
tumors may be guiding selection of ROIs to the area of
greatest malignant potential.
With improved imaging technology comes the potential
forenhancedtherapeuticmeasures.Speciﬁcally,thisincludes
directed therapeutic measures after labeled microbubbles are
used [2]. In a murine model this method has been shown
to accurately detect sites of active angiogenesis [24]. It is
possible that labeled microbubbles could provide directed
therapy.
In conclusion, it is hoped that this paper may contribute
to the development of new methods for diagnosing, enhanc-
ing therapy, and detecting tumor response for this dreaded
gynecologic malignancy, possibly with the use of targeted
microbubbles [2, 24–28].
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